We previously found that 82% of glial fibrillary acidic protein (GFAP)positive hippocampal astrocytes acutely isolated from P1-10 rats responded to glutamate (Glu) with transient intracellular calcium increases via activation of a Group I metabotropic glutamate receptor (mGluR). Fewer cells responde
Reduced expression of metabotropic glutamate receptor 2mRNA in T cells of ALS patients
โ Scribed by Cornelia Poulopoulou; Panagiota Davaki; Vassiliki Koliaraki; Dimitra Kolovou; Ioannis Markakis; Dimitrios Vassilopoulos
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 144 KB
- Volume
- 58
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Metabotropic glutamate receptors alter the vulnerability of neurons to excitotoxic damage and are reported to display abnormal expression in the central nervous system of ALS patients. Using reverse transcriptase polymerase chain reaction, we investigated the mRNA expression of specific metabotropic glutamate receptor subtypes in T lymphocytes of 20 patients with sporadic ALS, compared with healthy ageโmatched control subjects and patients with other neurological disorders. The levels of metabotropic glutamate receptor 2 mRNA were markedly reduced, whereas the expression of other subtypes (1b, 3, 8) was similar to control levels. Our findings may provide a reliable peripheral marker of the glutamatergic dysfunction that characterizes ALS. Ann Neurol 2006
๐ SIMILAR VOLUMES
Morphology, distribution and number of unipolar brush cells (UBCs) was studied in the cerebellar vermal lobules I-X of the chicken, rat, guinea pig, cat, and monkey using monoclonal mGluR1a antibody as a marker to visualise these recently described nerve cells (Mugnaini and Floris [1994] J. Comp. Ne
We and others have shown decreased expression of T-cell receptor-CD3-associated signal transducing molecules (TCR) in tumor infiltrating and peripheral T cells of patients with advanced cancer. In the present study, we performed adoptive immunotherapy (AIT) with tumor-associated lymphocytes (TAL) in